About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Silent Progression Activity Monitoring - SPAM Study

NCT05650281·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Centre Hospitalier Universitaire de Nice

Age

Any age

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

HAT start after April 12th 2007 (availability of Natalizumab)
Naive or failure (or intolerability) to 1 or more first line DMT (injectables, teriflunomide, DMF).

You may not be if

Progressive relapsing MS at baseline
Clinical or basic MRI data unavailable after on-site visit.
MS diagnostic \> 5 years at baseline
Immunosuppressive drugs (Azathioprine, Cyclophosphamide, Mycophenolate, Methotrexate) prescribed before HAT initiation

The record

StatusCompleted

PhaseNo phase

Taking part2,230

StartedJan 2023

UpdatedJul 21, 2023

Conditions

Multiple Sclerosis

Where1

CHU de Nice
Nice, France

Clareo Health | Silent Progression Activity Monitoring - SPAM Study